FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166372279> ?p ?o ?g. }

• W3166372279 endingPage "e18607" @default.
• W3166372279 startingPage "e18607" @default.
• W3166372279 abstract "e18607 Background: FN after myelosuppressive chemotherapy may result in significant morbidity/mortality and increase healthcare costs due to interventions such as hospitalization. For patients receiving chemotherapy at intermediate-risk of FN, guidelines recommend assessing patient-specific FN RFs to decide whether to provide primary prophylaxis. However, there is a paucity of real-world data that quantifies the FN risk based on patient RFs when receiving intermediate-risk chemotherapy. Thus, we examined the association of FN RFs with incident FN in the first and subsequent cycles in patients at intermediate-risk of chemotherapy-induced FN within the real-world. Methods: This retrospective cohort study used the Optum Research Database to identify US commercial and Medicare Advantage patients with a non-myeloid malignancy who were treated between 01 Jan 2009 and 31 Dec 2019 with a first-line intermediate-risk chemotherapy regimen. The following FN RFs were identified based on ICD or procedure codes on claims during the 6 months prior to chemotherapy, unless otherwise stated: radiation, neutropenia, liver dysfunction, renal dysfunction, age > 65 years, metastases to the bone, and surgery during the 30 days prior. FN was defined as ICD codes for neutropenia and fever on a claim. Patients without previous FN were followed for FN from five days after index through the earliest of the following: 1) FN, 2) 31 Dec 2019, 3) death, 4) health plan disenrollment, or 5) end of chemotherapy line or cycle (depending on time frame of interest). Cox regression was used to calculate HRs for incident FN. Results: The study included 13,937 patients, and the most common RFs were 1) recent surgery (84%), 2) age > 65 (67%), and 3) liver dysfunction (31%). Compared to patients with no individual RFs, each additional RF was associated with a greater risk of FN during both the first and subsequent cycles, although confidence intervals were large (Table). Conclusions: Among patients at intermediate-risk of chemotherapy-induced FN, patients with more individual RFs for FN had a higher risk of FN during both the first and all cycles. These results underscore the importance of RF analysis in prophylaxis decisions for patients at intermediate-risk of chemotherapy-induced FN.[Table: see text]" @default.
• W3166372279 created "2021-06-22" @default.
• W3166372279 creator A5011695068 @default.
• W3166372279 creator A5028393157 @default.
• W3166372279 creator A5040036696 @default.
• W3166372279 creator A5071873633 @default.
• W3166372279 creator A5073060840 @default.
• W3166372279 creator A5073300021 @default.
• W3166372279 date "2021-05-20" @default.
• W3166372279 modified "2023-10-16" @default.
• W3166372279 title "Association of febrile neutropenia (FN) risk factors (RFs) with incident FN in U.S. commercial and Medicare advantage patients receiving intermediate-risk chemotherapy for non-myeloid cancers between 2009 and 2019." @default.
• W3166372279 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e18607" @default.
• W3166372279 hasPublicationYear "2021" @default.
• W3166372279 type Work @default.
• W3166372279 sameAs 3166372279 @default.
• W3166372279 citedByCount "0" @default.
• W3166372279 crossrefType "journal-article" @default.
• W3166372279 hasAuthorship W3166372279A5011695068 @default.
• W3166372279 hasAuthorship W3166372279A5028393157 @default.
• W3166372279 hasAuthorship W3166372279A5040036696 @default.
• W3166372279 hasAuthorship W3166372279A5071873633 @default.
• W3166372279 hasAuthorship W3166372279A5073060840 @default.
• W3166372279 hasAuthorship W3166372279A5073300021 @default.
• W3166372279 hasConcept C126322002 @default.
• W3166372279 hasConcept C141071460 @default.
• W3166372279 hasConcept C143998085 @default.
• W3166372279 hasConcept C167135981 @default.
• W3166372279 hasConcept C2776694085 @default.
• W3166372279 hasConcept C2777063308 @default.
• W3166372279 hasConcept C2778336483 @default.
• W3166372279 hasConcept C2778850193 @default.
• W3166372279 hasConcept C50382708 @default.
• W3166372279 hasConcept C71924100 @default.
• W3166372279 hasConcept C72563966 @default.
• W3166372279 hasConceptScore W3166372279C126322002 @default.
• W3166372279 hasConceptScore W3166372279C141071460 @default.
• W3166372279 hasConceptScore W3166372279C143998085 @default.
• W3166372279 hasConceptScore W3166372279C167135981 @default.
• W3166372279 hasConceptScore W3166372279C2776694085 @default.
• W3166372279 hasConceptScore W3166372279C2777063308 @default.
• W3166372279 hasConceptScore W3166372279C2778336483 @default.
• W3166372279 hasConceptScore W3166372279C2778850193 @default.
• W3166372279 hasConceptScore W3166372279C50382708 @default.
• W3166372279 hasConceptScore W3166372279C71924100 @default.
• W3166372279 hasConceptScore W3166372279C72563966 @default.
• W3166372279 hasFunder F4320333100 @default.
• W3166372279 hasIssue "15_suppl" @default.
• W3166372279 hasLocation W31663722791 @default.
• W3166372279 hasOpenAccess W3166372279 @default.
• W3166372279 hasPrimaryLocation W31663722791 @default.
• W3166372279 hasRelatedWork W136411592 @default.
• W3166372279 hasRelatedWork W1975832547 @default.
• W3166372279 hasRelatedWork W1994502729 @default.
• W3166372279 hasRelatedWork W2016406397 @default.
• W3166372279 hasRelatedWork W2018507611 @default.
• W3166372279 hasRelatedWork W2034542762 @default.
• W3166372279 hasRelatedWork W2079537706 @default.
• W3166372279 hasRelatedWork W2096138651 @default.
• W3166372279 hasRelatedWork W2520789142 @default.
• W3166372279 hasRelatedWork W2949664805 @default.
• W3166372279 hasVolume "39" @default.
• W3166372279 isParatext "false" @default.
• W3166372279 isRetracted "false" @default.
• W3166372279 magId "3166372279" @default.
• W3166372279 workType "article" @default.